This is the only characterization of how SLU-PP-332 is metabolized by human tissue. Researchers incubated the compound with human liver S9 fraction and human liver microsomes and used high-resolution tandem mass spectrometry to identify nine metabolites, six Phase-I and three Phase-II, alongside reference analytical data for the parent compound. The work was performed for sports drug testing purposes, which is directly relevant because SLU-PP-332 is a WADA prohibited substance and that status must be disclosed to athlete patients. It is human-tissue metabolism data rather than a dosing study, so it reports no oral bioavailability figure.
For your business
SLU-PP-332 is WADA-prohibited; nine human-tissue metabolites identified, informing disclosure conversations with athlete patients.
Read more on Rapid communications in mass spectrometry : RCM →